RORC and cancer: Since therapeutic resistance is a major barrier to targeted therapy in iCCA and RORγ has been implicated in modulating drug sensitivity across cancers (e.g., castration-resistant prostate cancer and osteosarcoma), these observations prompted further investigation into RORγ’s potential role in pemigatinib-resistant iCCA [23, 24].